Product Code: ETC13319692 | Publication Date: Apr 2025 | Updated Date: Jul 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 190 | No. of Figures: 80 | No. of Tables: 40 |
According to 6Wresearch internal database and industry insights, the Global Glucagon Delivery Devices Market was valued at USD 1.1 Billion in 2024 and is expected to reach USD 1.61 Billion by 2031, growing at a compound annual growth rate of 5.60% during the forecast period (2025-2031).
The Global Glucagon Delivery Devices Market is experiencing steady growth due to the increasing prevalence of diabetes worldwide. Glucagon is a hormone used to treat severe hypoglycemia, a common complication of diabetes. The market is driven by the rising diabetic population, technological advancements in delivery devices, and the growing awareness about the importance of timely hypoglycemia management. Autoinjectors, prefilled syringes, and nasal sprays are the key product types in the market. North America holds a significant share in the market due to high healthcare expenditure and advanced healthcare infrastructure. However, the Asia-Pacific region is expected to witness the fastest growth due to the increasing adoption of advanced medical technologies and rising healthcare spending in countries like China and India. Key players in the market include Eli Lilly and Company, Xeris Pharmaceuticals, and Zealand Pharma.
The Global Glucagon Delivery Devices Market is witnessing significant growth driven by the rising prevalence of diabetes worldwide. Key trends include the increasing adoption of advanced delivery devices such as prefilled syringes, pens, and nasal sprays for convenient and accurate administration of glucagon. The market is also benefiting from the development of innovative technologies like smart devices that offer features such as dose tracking and reminders for improved patient compliance. Opportunities in the market lie in the untapped potential in emerging markets, the expanding diabetic population, and the growing focus on self-management of diabetes. Additionally, collaborations between pharmaceutical companies and device manufacturers to develop user-friendly, next-generation delivery devices are expected to drive further market growth in the coming years.
In the Global Glucagon Delivery Devices Market, challenges are primarily related to the adoption and awareness of glucagon among both patients and healthcare providers. Limited patient education about severe hypoglycemic events and the importance of glucagon administration during emergencies can hinder market growth. Additionally, the complexity of currently available glucagon delivery devices, such as needle phobia and the need for multiple steps in the administration process, can act as barriers to widespread usage. Furthermore, regulatory hurdles and pricing pressures in different regions pose challenges for market expansion. Overcoming these obstacles would require improved patient and healthcare provider education, development of user-friendly delivery devices, and addressing regulatory and pricing concerns to drive the market growth for glucagon delivery devices.
The Global Glucagon Delivery Devices Market is primarily driven by the increasing prevalence of diabetes worldwide, particularly type 1 diabetes, as glucagon is essential for treating severe hypoglycemia in diabetic patients. The rising awareness about the importance of prompt treatment for hypoglycemic episodes and the growing adoption of advanced delivery devices such as prefilled syringes, pens, and nasal sprays are also fueling market growth. Additionally, technological advancements in glucagon delivery systems, such as the development of stable formulations and user-friendly devices, are enhancing patient convenience and driving market demand. Moreover, the emphasis on improving diabetes management and the efforts to enhance emergency response strategies for hypoglycemic events are further propelling the market for glucagon delivery devices.
Government policies related to the Global Glucagon Delivery Devices Market vary by country and region, with some common themes emerging. In the United States, the FDA plays a key role in regulating medical devices, including glucagon delivery devices, to ensure their safety and efficacy. Reimbursement policies from government healthcare programs such as Medicare and Medicaid can influence the adoption and utilization of these devices. In Europe, the European Medicines Agency (EMA) provides regulatory oversight, and reimbursement decisions are made at the national level, impacting market access. Additionally, some countries may have specific guidelines or initiatives promoting the use of innovative medical technologies, which can create opportunities for manufacturers in the glucagon delivery devices market. Overall, government policies play a significant role in shaping the regulatory environment and market dynamics for glucagon delivery devices globally.
The Global Glucagon Delivery Devices Market is expected to witness significant growth in the coming years, driven by increasing awareness about hypoglycemia management, rising prevalence of diabetes, and technological advancements in drug delivery systems. The market is likely to be propelled by the development of innovative glucagon delivery devices that offer improved convenience, ease of use, and dosing accuracy for both patients and caregivers. Additionally, the growing adoption of wearable and connected devices for diabetes management is anticipated to further boost market growth. With a focus on enhancing patient outcomes and quality of life, manufacturers are likely to invest in research and development activities to introduce advanced glucagon delivery solutions, ultimately expanding the market size and creating new opportunities for growth in the global healthcare sector.
The Asia Pacific region is expected to witness significant growth in the global glucagon delivery devices market due to the increasing prevalence of diabetes and rising healthcare expenditure in countries like China and India. North America is projected to hold a substantial market share primarily driven by the presence of key market players, advanced healthcare infrastructure, and high adoption rates of innovative medical technologies. In Europe, the market is likely to experience steady growth owing to the growing awareness about diabetes management and increasing government initiatives to improve healthcare services. The Middle East and Africa region is expected to show moderate growth due to improving healthcare infrastructure and rising diabetes prevalence. Latin America is also anticipated to witness growth due to increasing healthcare investments and a growing diabetic population.
Global Glucagon Delivery Devices Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Global Glucagon Delivery Devices Market Overview |
3.1 Global Regional Macro Economic Indicators |
3.2 Global Glucagon Delivery Devices Market Revenues & Volume, 2021 & 2031F |
3.3 Global Glucagon Delivery Devices Market - Industry Life Cycle |
3.4 Global Glucagon Delivery Devices Market - Porter's Five Forces |
3.5 Global Glucagon Delivery Devices Market Revenues & Volume Share, By Regions, 2021 & 2031F |
3.6 Global Glucagon Delivery Devices Market Revenues & Volume Share, By Device Type, 2021 & 2031F |
3.7 Global Glucagon Delivery Devices Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.8 Global Glucagon Delivery Devices Market Revenues & Volume Share, By End user, 2021 & 2031F |
3.9 Global Glucagon Delivery Devices Market Revenues & Volume Share, By Reimbrusment, 2021 & 2031F |
4 Global Glucagon Delivery Devices Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Global Glucagon Delivery Devices Market Trends |
6 Global Glucagon Delivery Devices Market, 2021 - 2031 |
6.1 Global Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Global Glucagon Delivery Devices Market, Revenues & Volume, By Injectable Glucagon, 2021 - 2031 |
6.1.3 Global Glucagon Delivery Devices Market, Revenues & Volume, By Nasal Glucagon, 2021 - 2031 |
6.1.4 Global Glucagon Delivery Devices Market, Revenues & Volume, By Oral Glucagon, 2021 - 2031 |
6.2 Global Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Global Glucagon Delivery Devices Market, Revenues & Volume, By Severe Hypoglycemia, 2021 - 2031 |
6.2.3 Global Glucagon Delivery Devices Market, Revenues & Volume, By Type 1 Diabetes, 2021 - 2031 |
6.2.4 Global Glucagon Delivery Devices Market, Revenues & Volume, By Type 2 Diabetes, 2021 - 2031 |
6.3 Global Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Global Glucagon Delivery Devices Market, Revenues & Volume, By Adults, 2021 - 2031 |
6.3.3 Global Glucagon Delivery Devices Market, Revenues & Volume, By Pediatric Population, 2021 - 2031 |
6.4 Global Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Global Glucagon Delivery Devices Market, Revenues & Volume, By Commercial Insurance, 2021 - 2031 |
6.4.3 Global Glucagon Delivery Devices Market, Revenues & Volume, By Medicare, 2021 - 2031 |
6.4.4 Global Glucagon Delivery Devices Market, Revenues & Volume, By Medicaid, 2021 - 2031 |
7 North America Glucagon Delivery Devices Market, Overview & Analysis |
7.1 North America Glucagon Delivery Devices Market Revenues & Volume, 2021 - 2031 |
7.2 North America Glucagon Delivery Devices Market, Revenues & Volume, By Countries, 2021 - 2031 |
7.2.1 United States (US) Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
7.2.2 Canada Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
7.2.3 Rest of North America Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
7.3 North America Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
7.4 North America Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
7.5 North America Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
7.6 North America Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
8 Latin America (LATAM) Glucagon Delivery Devices Market, Overview & Analysis |
8.1 Latin America (LATAM) Glucagon Delivery Devices Market Revenues & Volume, 2021 - 2031 |
8.2 Latin America (LATAM) Glucagon Delivery Devices Market, Revenues & Volume, By Countries, 2021 - 2031 |
8.2.1 Brazil Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
8.2.2 Mexico Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
8.2.3 Argentina Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
8.2.4 Rest of LATAM Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
8.3 Latin America (LATAM) Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
8.4 Latin America (LATAM) Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
8.5 Latin America (LATAM) Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
8.6 Latin America (LATAM) Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
9 Asia Glucagon Delivery Devices Market, Overview & Analysis |
9.1 Asia Glucagon Delivery Devices Market Revenues & Volume, 2021 - 2031 |
9.2 Asia Glucagon Delivery Devices Market, Revenues & Volume, By Countries, 2021 - 2031 |
9.2.1 India Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
9.2.2 China Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
9.2.3 Japan Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
9.2.4 Rest of Asia Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
9.3 Asia Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
9.4 Asia Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
9.5 Asia Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
9.6 Asia Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
10 Africa Glucagon Delivery Devices Market, Overview & Analysis |
10.1 Africa Glucagon Delivery Devices Market Revenues & Volume, 2021 - 2031 |
10.2 Africa Glucagon Delivery Devices Market, Revenues & Volume, By Countries, 2021 - 2031 |
10.2.1 South Africa Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
10.2.2 Egypt Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
10.2.3 Nigeria Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
10.2.4 Rest of Africa Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
10.3 Africa Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
10.4 Africa Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
10.5 Africa Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
10.6 Africa Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
11 Europe Glucagon Delivery Devices Market, Overview & Analysis |
11.1 Europe Glucagon Delivery Devices Market Revenues & Volume, 2021 - 2031 |
11.2 Europe Glucagon Delivery Devices Market, Revenues & Volume, By Countries, 2021 - 2031 |
11.2.1 United Kingdom Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
11.2.2 Germany Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
11.2.3 France Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
11.2.4 Rest of Europe Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
11.3 Europe Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
11.4 Europe Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
11.5 Europe Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
11.6 Europe Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
12 Middle East Glucagon Delivery Devices Market, Overview & Analysis |
12.1 Middle East Glucagon Delivery Devices Market Revenues & Volume, 2021 - 2031 |
12.2 Middle East Glucagon Delivery Devices Market, Revenues & Volume, By Countries, 2021 - 2031 |
12.2.1 Saudi Arabia Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
12.2.2 UAE Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
12.2.3 Turkey Glucagon Delivery Devices Market, Revenues & Volume, 2021 - 2031 |
12.3 Middle East Glucagon Delivery Devices Market, Revenues & Volume, By Device Type, 2021 - 2031 |
12.4 Middle East Glucagon Delivery Devices Market, Revenues & Volume, By Indication, 2021 - 2031 |
12.5 Middle East Glucagon Delivery Devices Market, Revenues & Volume, By End user, 2021 - 2031 |
12.6 Middle East Glucagon Delivery Devices Market, Revenues & Volume, By Reimbrusment, 2021 - 2031 |
13 Global Glucagon Delivery Devices Market Key Performance Indicators |
14 Global Glucagon Delivery Devices Market - Export/Import By Countries Assessment |
15 Global Glucagon Delivery Devices Market - Opportunity Assessment |
15.1 Global Glucagon Delivery Devices Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Global Glucagon Delivery Devices Market Opportunity Assessment, By Device Type, 2021 & 2031F |
15.3 Global Glucagon Delivery Devices Market Opportunity Assessment, By Indication, 2021 & 2031F |
15.4 Global Glucagon Delivery Devices Market Opportunity Assessment, By End user, 2021 & 2031F |
15.5 Global Glucagon Delivery Devices Market Opportunity Assessment, By Reimbrusment, 2021 & 2031F |
16 Global Glucagon Delivery Devices Market - Competitive Landscape |
16.1 Global Glucagon Delivery Devices Market Revenue Share, By Companies, 2024 |
16.2 Global Glucagon Delivery Devices Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Top 10 Company Profiles |
18 Recommendations |
19 Disclaimer |